203 related articles for article (PubMed ID: 28403629)
1. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
4. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.
Wang Y; He T; Herman JG; Linghu E; Yang Y; Fuks F; Zhou F; Song L; Guo M
Clin Epigenetics; 2017; 9():115. PubMed ID: 29075358
[TBL] [Abstract][Full Text] [Related]
5. Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin.
Peng Y; Wang L; Wu L; Zhang L; Nie G; Guo M
J Cancer; 2019; 10(24):6124-6134. PubMed ID: 31762822
[No Abstract] [Full Text] [Related]
6. Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development.
Gao D; Han Y; Yang Y; Herman JG; Linghu E; Zhan Q; Fuks F; Lu ZJ; Guo M
Epigenetics; 2017 Jul; 12(7):575-583. PubMed ID: 28678648
[TBL] [Abstract][Full Text] [Related]
7. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.
Pelosof L; Yerram S; Armstrong T; Chu N; Danilova L; Yanagisawa B; Hidalgo M; Azad N; Herman JG
Epigenetics; 2017 Jul; 12(7):540-550. PubMed ID: 27918237
[TBL] [Abstract][Full Text] [Related]
8. Methylation of
Zheng R; Gao D; He T; Zhang M; Zhang X; Linghu E; Wei L; Guo M
Clin Epigenetics; 2017; 9():50. PubMed ID: 28491151
[TBL] [Abstract][Full Text] [Related]
9. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
[TBL] [Abstract][Full Text] [Related]
10. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
[TBL] [Abstract][Full Text] [Related]
11. Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma.
Galamb O; Kalmár A; Barták BK; Patai ÁV; Leiszter K; Péterfia B; Wichmann B; Valcz G; Veres G; Tulassay Z; Molnár B
World J Gastroenterol; 2016 Dec; 22(47):10325-10340. PubMed ID: 28058013
[TBL] [Abstract][Full Text] [Related]
12. Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
Kuhmann C; Li C; Kloor M; Salou M; Weigel C; Schmidt CR; Ng LW; Tsui WW; Leung SY; Yuen ST; Becker N; Weichenhan D; Plass C; Schmezer P; Chan TL; Popanda O
Hum Mol Genet; 2014 Apr; 23(8):2043-54. PubMed ID: 24282031
[TBL] [Abstract][Full Text] [Related]
13. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of NDRG2 promotes colorectal cancer proliferation and invasion.
Hong SN; Kim SJ; Kim ER; Chang DK; Kim YH
J Gastroenterol Hepatol; 2016 Jan; 31(1):164-71. PubMed ID: 26250123
[TBL] [Abstract][Full Text] [Related]
15. High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.
Deng Y; Cai Y; Huang Y; Yang Z; Bai Y; Liu Y; Deng X; Wang J
BMC Cancer; 2015 Nov; 15():833. PubMed ID: 26525741
[TBL] [Abstract][Full Text] [Related]
16. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
[No Abstract] [Full Text] [Related]
19. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
